Label update also includes approval of combination therapy with basal insulin for the treatment of adults with type 2 diabetes.
The update is based on data from two randomized, open-label studies in adults with type 2 diabetes.
Novo Nordisk executive vice president and chief science officer Mads Thomsen said: "The data from these studies further demonstrate the strong clinical profile and the value of Victoza in the treatment of type 2 diabetes."